Galderma Group AG

As of December 31, 2025, Galderma Group AG carries a market capitalization of 38.07B, placing it among publicly traded companies globally. Its enterprise value stands at 39.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Galderma Group AG's next confirmed earnings release is scheduled for March 11, 2027.

As of December 31, 2025, Galderma Group AG has 234.57M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Galderma Group AG maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Galderma Group AG's stock has gained approximately 36.98% over the past 52 weeks. The 50-day moving average sits at 165.40, while the 200-day moving average is 162.04.

As of December 31, 2025, Galderma Group AG holds 618.06M in cash and equivalents against 2.18B in total debt, resulting in a net debt position of 1.45B. Total book value stands at 6.46B, with working capital of 302.69M providing operational flexibility.